Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic reports “positive preclinical results” in oncology and immunology as it prepares to move drug candidates toward clinical trials.
Greenoaks and Sequoia Capital co-led the $5 billion Series C, with Andreessen Horowitz joining and all existing backers participating. The money will support further development of its AI drug-design engine and expansion into more types of medicine. The round follows a $2.1 billion Series B in May. Isomorphic did not disclose its valuation; Bloomberg previously reported it was seeking $50 billion.
TechCrunch AI's note
Greenoaks and Sequoia Capital co-led the $5 billion Series C, with Andreessen Horowitz joining and all existing backers participating. The money will support further development of its AI drug-design engine and expansion into more types of medicine. The round follows a $2.1 billion Series B in May. Isomorphic did not disclose its valuation; Bloomberg previously reported it was seeking $50 billion.
TechCrunch AI's note
score 9